- Home
- IKNA vs IPSC Comparison
IKNA vs IPSC Comparison
Compare IKNA & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- IPSC
- Stock Information
- Founded
- IKNA 2016
- IPSC 2019
- Country
- IKNA United States
- IPSC United States
- Employees
- IKNA N/A
- IPSC N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- IKNA Health Care
- IPSC Health Care
- Exchange
- IKNA Nasdaq
- IPSC Nasdaq
- Market Cap
- IKNA 52.1M
- IPSC 48.2M
- IPO Year
- IKNA 2021
- IPSC 2021
- Fundamental
- Price
- IKNA $1.19
- IPSC $0.53
- Analyst Decision
- IKNA Buy
- IPSC Strong Buy
- Analyst Count
- IKNA 2
- IPSC 5
- Target Price
- IKNA $3.00
- IPSC $3.33
- AVG Volume (30 Days)
- IKNA 109.0K
- IPSC 719.1K
- Earning Date
- IKNA 05-08-2025
- IPSC 05-15-2025
- Dividend Yield
- IKNA N/A
- IPSC N/A
- EPS Growth
- IKNA N/A
- IPSC N/A
- EPS
- IKNA N/A
- IPSC N/A
- Revenue
- IKNA N/A
- IPSC $114,898,000.00
- Revenue This Year
- IKNA N/A
- IPSC $833.10
- Revenue Next Year
- IKNA N/A
- IPSC N/A
- P/E Ratio
- IKNA N/A
- IPSC N/A
- Revenue Growth
- IKNA N/A
- IPSC 8286.72
- 52 Week Low
- IKNA $0.97
- IPSC $0.34
- 52 Week High
- IKNA $1.94
- IPSC $3.46
- Technical
- Relative Strength Index (RSI)
- IKNA 53.94
- IPSC 46.73
- Support Level
- IKNA $1.10
- IPSC $0.48
- Resistance Level
- IKNA $1.20
- IPSC $0.59
- Average True Range (ATR)
- IKNA 0.08
- IPSC 0.04
- MACD
- IKNA 0.01
- IPSC -0.00
- Stochastic Oscillator
- IKNA 74.26
- IPSC 34.62
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.